Leuvas Therapeutics is a biopharmaceutical company developing therapeutics that block leukocyte-vascular interactions (LVI) to develope therapeutics for Refractory epilepsy, Epileptogenesis (following seizure, TBI, stroke) and Alzheimers disease.
Leuvas Therapeutics, Inc.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttp://www.leuvas.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address2416 Tamalpais St,CA 94043-4130Mountain ViewUnited States
2416 Tamalpais St,CA 94043-4130
Mountain View
United States
Contact Number+1 650-968-8625
+1 650-968-8625
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Leuvas is leveraging on recent discoveries that dysfunctional endothelium, inflammatory vascular changes and leukocyte-vascular interactions (LVI) underlie disease pathogenesis in epilepsy, Alzheimers Disease and other neurodegenerative diseases.